Autor

/Autor

About Autor

This author has not yet filled in any details.
So far Autor has created 1032 blog entries.

Atlanta’s first ‘smart neighborhood’ moves forward on the Westside

Atlanta's first "smart neighborhood," a development of Georgia Power and PulteGroup, is moving forward in construction efforts, and added four new partners to the project. Located in Atlanta's upper Westside, plans are moving along for a 46-townhouse ...

By | 2019-03-20T11:23:57+00:00 March 20th, 2019|Technology|

Meet Group CEO: livestream ‘talent’ to double dating app ‘gift’ sales

Meet Group CEO Geoff Cook spoke at an investor conference Tuesday, outlining their plan to double dating app video livestream revenue in 2019 and what they look for in acquisitions.

By | 2019-03-20T11:18:18+00:00 March 20th, 2019|Technology|

SunTrust, BB&T still working on new name, CEO Rogers says

The name game is still underway. SunTrust Banks Inc. CEO Bill Rogers says he doesn’t yet know what the name of his company will be after it merges with BB&T Corp. (NYSE: BBT), nor does he know what the name of the Atlanta Braves’ SunTrust Park will be...

By | 2019-03-20T11:02:11+00:00 March 20th, 2019|Economics|

Executive Pursuits: Springtime fishing brings questions, answers

It's the first day of spring. Time to gather your fishing gear, go to the library or bookstore, and prepare to collect your thoughts. Even if you don’t catch what you are looking for, you’ll still be glad you made the trip.

By | 2019-03-20T08:30:00+00:00 March 20th, 2019|Education|

Jury finds Bayer’s Roundup as factor in cancer case

A federal jury in San Francisco ruled Tuesday that the weedkiller Roundup, a product developed by Monsanto that was acquired by Bayer, played a significant role in a man’s cancer.  Edwin Hardeman, a California resident, used the weedkiller in his yard...

By | 2019-03-20T00:02:49+00:00 March 20th, 2019|Healthcare|

FDA approves Sage’s first-ever treatment for postpartum depression

The FDA has approved Cambridge biopharma Sage Therapeutics' first product, a drug that the company says will be the first product specifically designed to treat postpartum depression. Zulresso is Sage's (Nasdaq: SAGE) first product to reach the marke...

By | 2019-03-19T21:53:24+00:00 March 19th, 2019|Healthcare|